Wedemeyer, HeinerYurdaydin, CihanErnst, StefanieCaruntu, Florin A.Curescu, Manuela G.Yalcin, KendalAkarca, Ulus S.Zeuzem, StefanErhardt, AndreasLueth, StefanPapatheodoridis, GeorgeKeskin, OnurPort, KerstinCelen, Mustafa K.Stift, JudithHeidrich, BenjaminMederacke, IngmarHardtke, SvenjaKoch, ArminDienes, Hans P.Manns, Michael P.2024-08-162024-08-162013-10-010270-9139https://hdl.handle.net/11452/44125Bu çalışma, 01-05 Kasım2013 tarihleri arasında Washington [ABD]’da düzenlenen 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases’da bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessScience & technologyLife sciences & biomedicineGastroenterology & hepatology96 weeks of pegylated-interferon- alpha-2α plus tenofovir or placebo for the treatment of hepatitis delta: The hidit-2 studyMeeting Abstract000330252201031222A223A58Supplement1, Special IssueSI